Here’s Why Eli Lilly Could Want Abivax’s Oral UC Therapy (NASDAQ:ABVX)

Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy Summary Abivax surged 1,470% YTD, driven by Obefazimod's clinical progress and takeover speculation, but I rate it Hold due to valuation risk. Obefazimod, a first-in-class oral therapy for ulcerative colitis, met key Phase 3 endpoints, with pivotal maintenance data expected mid-2026. ABVX boasts €589.7 million in cash, supporting operations through Q4 2027, despite high R&D-driven losses and a €15.3 million monthly cash burn. Takeover rumors by Eli Lilly have fueled recent gains, but absent a deal, I anticipate a sharp pullback given extreme valuation multiples. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Preview: ~253 words